


ECRM PTO-1390 (REV 07-2005)		ATTORNEY DOCKET NUMBER - 4439-4043
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TBA 10/581158
INTERNATIONAL APPLICATION PCT/JP2004/017428	INTERNATIONAL FILING DATE 24 November 2004	EARLIEST PRIORITY DATE CLAIMED 1 December 2003
TITLE OF INVENTION NOVEL CENTROMERIC PROTEIN SHUGOSHIN		
APPLICANT(S) FOR DO/EO/US Yoshinori WATANABE		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.		
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.		
3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.		
4. <input checked="" type="checkbox"/> The US has been elected. (Article 31).		
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))		
a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).		
6. <input checked="" type="checkbox"/> An English language translation of the International application as filed (35 U.S.C. 371(c)(2)).		
a. <input checked="" type="checkbox"/> is attached hereto (Specification: 45 pgs., Claims: 5 pgs.; Abstract: 1 pg.; and 13 Sheets of Formal Drawings (Figs. 1a-1d, 2, 3a-3d, 4a-4g, 5-6, 7a-7e, 8a-8h, 9-10, 11a-11b, 12, 13a-13d, 14-15, 16a-16d, 17a-17d, and 18)). b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).		
7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))		
a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made.		
8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).		
10. <input type="checkbox"/> An English translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11 to 20 below concern document(s) or information included:		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Forms PTO-1449A and PTO-1449B, with copies of all cited references.		
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
13. <input type="checkbox"/> A preliminary amendment.		
14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.		
15. <input type="checkbox"/> A substitute specification.		
16. <input type="checkbox"/> A power of attorney and/or change of address letter.		
17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821-1.825 with the paper copy of the sequence listings: 52 pgs. and Sequence Listing Statement.		
18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).		
19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).		
20. <input checked="" type="checkbox"/> Other items or Information:		
Copies of: PCT Request document; Forms: PCT/ISA/202; PCT/ISA/206; PCT/ISA/210; PCT/ISA/220; PCT/ISA/237; PCT/IB/301; PCT/IB/304, PCT/IB/308; and published PCT application Publication Number WO 2005/054471 A1, published on 16 June 2005.		

U.S. APPLICATION NO. (known) 10/581150		INTERNATIONAL APPLICATION NO. PCT/JP2004/017428		ATTORNEY'S DOCKET NO. 4439-4043	
TBA		PCT/JP2004/017428		4439-4043	
The following fees have been submitted				CALCULATIONS	PTO USE ONLY
21. <input checked="" type="checkbox"/> Basic national fee\$300				\$ 300	
22. <input checked="" type="checkbox"/> Examination fee If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33 (1)-(4).....\$0 All other situations.....\$200				\$ 200	
23. <input checked="" type="checkbox"/> Search fee If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1) - (4)\$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority.....\$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB.....\$400 All other situations.....\$500				\$ 400	
TOTAL OF 21, 22 and 23 =				\$ 900	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
- 100 =	/50 =		x \$250.00	\$----	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).				\$-----	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	48 - 20 =	- 28	x \$50.00	\$1,400	
Independent claims	20 - 3 =	- 17	x \$200.00	\$3,400	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$ 360	
TOTAL OF ABOVE CALCULATIONS =				\$6,060	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					
SUBTOTAL =				\$6,060	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				+	
TOTAL NATIONAL FEE =				\$6,060	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	
TOTAL FEES ENCLOSED =					
				Amount to be refunded:	\$
				Amount to be charged:	\$
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>13-4500 (Order No. 4439-4043)</u> in the amount of \$6,060 cover the above fees.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-4500 (Order No. 4439-4043)</u>.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <p>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <p>Enter Address Here Morgan & Finnegan, L.L.P. 3 World Financial Center New York, New York 10281-2101 Tel: (212) 415-8700 Fax: (212) 415-8701</p> <div style="text-align: right;">  Signature Kenneth H. Sonnenfeld / Michael A. Willis Name Registration Nos: 33,285 / 53,913 REGISTRATION NUMBER </div>					

IN THE UNITED STATES



RECEIVED PCT/PTO 31 MAY 2006
 DESIGNATED OFFICE (DO/US)
 ELECTED OFFICE (EO/US)

INTERNATIONAL APPLICATION PCT/JP2004/017428	INTERNATIONAL FILING DATE 24 November 2004	EARLIEST PRIORITY DATE CLAIMED 1 December 2003
TITLE OF INVENTION NOVEL CENTROMERIC PROTEIN SHUGOSHIN		
APPLICANT(S) FOR DO/EO/US Yoshinori WATANABE		

Mail Stop PCT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

ATTN: DO/EO/US

**VERIFIED CERTIFICATION OF EXPRESS MAILING DATE
 (INTERNATIONAL APPLICATION (37 CFR 1.10(c)))**

I declare that on May 31, 2006, I deposited with the United States Postal Service in an envelope "Express Mail, Post Office to Addressee", bearing Label Number EV 826870200 US, addressed to the Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Attention: DO/EO/US and having an express mail certification which I executed, the following papers:

1. Transmittal Letter to the United States Designated/Elected Office;
2. English Translation of the International Application: (Specification: 45 pgs., Claims: 5 pgs.; Abstract: 1 pg.; and 13 Sheets of Formal Drawings (Figs. 1a-1d, 2, 3a-3d, 4a-4g, 5-6, 7a-7e, 8a-8h, 9-10, 11a-11b, 12, 13a-13d, 14-15, 16a-16d, 17a-17d, and 18));
3. Sequence Listing Statement;
4. Paper Copy of the Sequence Listing (52 pgs.) with a computer-readable form of the sequence listing;
5. Copies of: PCT Request document; Forms: PCT/ISA/202; PCT/ISA/206; PCT/ISA/210; PCT/ISA/220; PCT/ISA/237; PCT/IB/301; PCT/IB/304; PCT/IB/308; and published PCT application Publication Number WO 2005/054471 A1, published on 16 June 2005.
6. Return receipt postcard.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Michael Willis

(Typed or printed name of person making this verified statement)

May 31, 2006

Date



(Signature of person making this verified statement)

(Verified Certification of Express Mailing Date (International Application) [13-12])